CNBX Pharmaceuticals Inc. (CNBX): R&D Expense
$0
Year ended 2025-08-31
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-08-31 | $0 | -100.0% | 2025-12-01, From 2024-09-01 |
| 2024-08-31 | $194.8K | -54.9% | 2025-12-01, From 2023-09-01 |
| 2023-08-31 | $431.6K | -63.5% | 2024-11-29, From 2022-09-01 |
| 2022-08-31 | $1.18M | -33.2% | 2023-11-30, From 2021-09-01 |
| 2021-08-31 | $1.77M | +5.3% | 2022-11-30, From 2020-09-01 |
| 2020-08-31 | $1.68M | +9.0% | 2021-11-29, From 2019-09-01 |
| 2019-08-31 | $1.54M | +53.8% | 2020-11-04, From 2018-09-01 |
| 2018-08-31 | $1.00M | +306.5% | 2019-11-29, From 2017-09-01 |
| 2017-08-31 | $246.9K | +39.0% | 2018-11-29, From 2016-09-01 |
| 2016-08-31 | $177.6K | +27.4% | 2017-12-08, From 2015-09-01 |
| 2015-08-31 | $139.4K | n/a | 2016-12-13, From 2014-09-01 |
| 2014-08-31 | $0 | n/a | 2016-01-07, From 2013-09-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| CNBX Pharmaceuticals Inc. (CNBX) | 2025-08-31 | $0 | -100.0% |
| Abbott Laboratories (ABT) | 2025-12-31 | $2.94B | +3.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $9.95B | -10.8% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $13.34B | +21.3% |
| Pfizer Inc (PFE) | 2025-12-31 | $10.44B | -3.6% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $14.66B | -14.9% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $1.90M | +11.8% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $15.79B | -12.0% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $1.90M | -7.5% |
Compare CNBX, ABT, BMY, LLY side by side · Screen every company in Pharmaceutical Preparations ↗